EGFR mutation positive stage IV non-small-cell lung cancer : Treatment beyond progression

EGFR mutation positive stage IV non-small-cell lung cancer : Treatment beyond progression

Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer for both men en women. Chemotherapy is the mainstay of treatment in advanced disease, but is only marginally effective. In about 30% of patients with advanced NSCLC in East Asia and in 10-15% in Western countries, EGFR muta...

Full description

Bibliographic Details
Main Authors: Katrijn eVan Assche, Katrien eVandecasteele, Liesbeth eFerdinande, Yolande eLievens, Veerle eSurmont
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-12-01
Series:Frontiers in Oncology
Subjects:
Radiotherapy
tyrosine kinase inhibitor
advanced non-small-cell lung cancer
EGFR mutation
local progression
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00350/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00350/full

Similar Items